Treatment of Cerebral Venous Thrombosis Due to Antiphospholipid Antibodies

Acute Phase Management

For patients with CVT due to antiphospholipid antibodies, initiate anticoagulation immediately with low-molecular-weight heparin or unfractionated heparin, then transition to adjusted-dose vitamin K antagonist (warfarin) targeting INR 2.0-3.0 (target 2.5) for long-term therapy, avoiding direct oral anticoagulants especially in triple-positive patients 1, 2, 3
Initial anticoagulation is essential and should begin immediately upon diagnosis, with low-molecular-weight heparin (LMWH) as the preferred initial agent over unfractionated heparin for acute CVT 4
Anticoagulation should be initiated even in the presence of hemorrhagic transformation, as this is standard practice for CVT regardless of etiology 1, 2

Vitamin K antagonist (warfarin) with target INR 2.5 (range 2.0-3.0) is the recommended long-term therapy for patients meeting criteria for antiphospholipid syndrome 1, 2, 3
Direct oral anticoagulants (DOACs) should be avoided in APLA syndrome patients, particularly those who are triple-positive, due to increased risk of thrombotic events 5, 3
The American College of Chest Physicians suggests adjusted-dose VKA over DOACs during the treatment phase for confirmed APS 5

Minimum duration of at least 3 months is reasonable for acute CVT 1, 2
For patients meeting full criteria for antiphospholipid syndrome, long-term indefinite anticoagulation is indicated 2, 3

Low-dose aspirin (75-100 mg daily) can be added to anticoagulation for high-risk APLA profiles, including triple-positive patients 3
Hydroxychloroquine should be continued if the patient has underlying systemic lupus erythematosus 3

Never use DOACs as first-line therapy in APLA-associated CVT, as the evidence supporting VKA superiority is strong, particularly in triple-positive patients 5, 3
Avoid estrogen-containing contraceptives in women with positive antiphospholipid antibodies due to significantly increased thrombosis risk 3
Ensure APLA testing is repeated after 12 weeks to confirm persistence before diagnosing antiphospholipid syndrome 3

For pregnant women with APLA and CVT, use adjusted-dose LMWH throughout pregnancy rather than warfarin (teratogenic in first trimester) 6, 4, 1, 2
Combine LMWH with low-dose aspirin (75-100 mg daily) during pregnancy 6, 4, 3